About Sulfotransferase 1A4
Sulfotransferase 1A4 (SULT1A4) is a protein
from Homo sapiens identified by UniProt accession
P0DMN0, 295 residues long.
MolForge cross-references it against 0 known binders and
38 disease associations.
Target properties
| Protein name | Sulfotransferase 1A4 |
| UniProt accession | P0DMN0 |
| Gene | SULT1A4 |
| Organism | Homo sapiens |
| Length | 295 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (38)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- Hepatic veno-occlusive disease - immunodeficiency · score 0.04
- congenital dyserythropoietic anemia type 2 · score 0.04
- Congenital dyserythropoietic anemia type II · score 0.04
- Senior-Boichis syndrome · score 0.04
- sclerosing cholangitis · score 0.03
- hemolytic anemia due to glucophosphate isomerase deficiency · score 0.03
- progressive familial intrahepatic cholestasis type 3 · score 0.03
- non-spherocytic hemolytic anemia due to hexokinase deficiency · score 0.03
- idiopathic hypereosinophilic syndrome · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P0DMN0-F1 | alphafold | PREDICTED | 96.56 | — |
Amino-acid sequence (295 residues)
MELIQDTSRP PLEYVKGVPL IKYFAEALGP LQSFQARPDD LLINTYPKSG TTWVSQILDM IYQGGDLEKC NRAPIYVRVP FLEVNDPGEP SGLETLKDTP PPRLIKSHLP LALLPQTLLD QKVKVVYVAR NPKDVAVSYY HFHRMEKAHP EPGTWDSFLE KFMAGEVSYG SWYQHVQEWW ELSRTHPVLY LFYEDMKENP KREIQKILEF VGRSLPEETM DFMVQHTSFK EMKKNPMTNY TTVPQELMDH SISPFMRKGM AGDWKTTFTV AQNERFDADY AEKMAGCSLS FRSEL
Explore Sulfotransferase 1A4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets